Diabetic retinopathy risks studied

Article

Severity linked to progression; younger age, macular oedema may also be involved

Interesting new findings have emerged from a study of the risk factors for the development and progression of diabetic retinopathy, namely, that its severity determines the rate of progression, especially in younger patients.

"Diabetic retinopathy is the major cause of visual impairment and blindness worldwide," said Dr Tan, consultant, Department of Ophthalmology, Tan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore.

"One reason for this may be the interrelationships among the various risk factors," he explained.

In light of these discrepancies, Dr Tan and colleagues studied patients with the disease over the course of 5 years as well as the risk factors associated with different facets of the disease: pre-existing diabetic retinopathy, the development and rate of progression of diabetic retinopathy, and development of clinically relevant diabetic macular oedema.

A total of 250 patients (mean age, 66 years) (500 eyes) with type 2 diabetes were included and followed for more than 5 years. Patients with coexisting ocular pathologies or a history of ocular surgeries were excluded. The diabetic retinopathy was graded using the Early Treatment of Diabetic Retinopathy Study classification. The results underwent univariate and multivariate analyses.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.